Jeffrey Albers - Blueprint Medicines President CEO, Director
| BPMC Stock | USD 94.86 3.52 3.85% |
CEO
Mr. Jeffrey W. Albers, J.D., serves as President, Chief Executive Officer and Director of the Company. Mr. Albers has served as our president and chief executive officer and a member of our board of directors since July 2014. In addition, Mr. Albers currently serves on the board of directors, audit committee and compensation committee of Magenta Therapeutics, Inc. and on the board of directors of the New England Division of the American Cancer Society. Mr. Albers has nearly a decade of experience in leadership roles in the biopharmaceutical industry. Prior to joining us, from January 2012 to April 2014, he was president of Algeta ASA, or Algeta, a Norwegian biopharmaceutical company, where he oversaw the commercial and business functions. At Algeta, Mr. Albers was responsible for the U.S. launch of Radium223 in metastatic castrate resistant prostate cancer. Prior to Algeta, from July 2005 to November 2011, Mr. Albers was at Genzyme Corporationrationration, or Genzyme, a biotechnology company that is now a whollyowned subsidiary of Sanofi S.A., most recently as vice president of the U.S. hematology and oncology business unit since 2014.
| Age | 46 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 45 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 374 7580 |
| Web | https://www.blueprintmedicines.com |
Jeffrey Albers Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Albers against Blueprint Medicines stock is an integral part of due diligence when investing in Blueprint Medicines. Jeffrey Albers insider activity provides valuable insight into whether Blueprint Medicines is net buyers or sellers over its current business cycle. Note, Blueprint Medicines insiders must abide by specific rules, including filing SEC forms every time they buy or sell Blueprint Medicines'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Albers over a month ago Disposition of 10000 shares by Jeffrey Albers of Blueprint Medicines at 15.01 subject to Rule 16b-3 |
Blueprint Medicines Management Efficiency
The company has return on total asset (ROA) of (0.2534) % which means that it has lost $0.2534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5714) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of May 2, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.Similar Executives
| Found 3 records | CEO Age | ||
| James Clark | LSI Industries | 53 | |
| Dennis Wells | LSI Industries | 55 | |
| Ronald Brown | LSI Industries | 63 | |
Management Performance
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 |
Blueprint Medicines Corp Leadership Team
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Lydon, Director | ||
| Michael Landsittel, Interim Principal Accounting and Financial Officer and Sr. Director of Fin. | ||
| George Demetri, Independent Director | ||
| Dr MBA, Chief Officer | ||
| Anthony Boral, Senior Vice President - Clinical Development | ||
| Tracey Esq, Chief VP | ||
| Kathryn Haviland, Chief Business Officer | ||
| Jeffrey Albers, President CEO, Director | ||
| Alexis Borisy, Director | ||
| Stephen Knight, Director | ||
| Christopher Murray, Senior Vice President Technical Operations | ||
| Tracey McCain, Executive Vice President Chief Legal Officer, Secretary | ||
| Alexis AM, CoFounder Director | ||
| Daniel Lynch, Chairman of the Board | ||
| Marion Dorsch, Chief Scientific Officer | ||
| Mark Goldberg, Director | ||
| Fouad MD, President Development | ||
| Kristin Hodous, IR Contact Officer | ||
| Charles Rowland, Independent Director | ||
| Ariel Hurley, Principal Accounting Officer | ||
| Christina Rossi, Chief Commercial Officer | ||
| Lonnel Coats, Independent Director | ||
| JD MBA, Ex Chairman | ||
| Jenna Cohen, Director Relations | ||
| Christoph Lengauer, Chief Scientific Officer | ||
| Thilo Schroeder, Director | ||
| Lynn Seely, Director |
Blueprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Blueprint Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (2.03) % | ||||
| Operating Margin | (1.46) % | ||||
| Current Valuation | 5.66 B | ||||
| Shares Outstanding | 62.81 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 4.25 M | ||||
| Price To Earning | 7.93 X |
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving together with Blueprint Stock
| 0.78 | VKTX | Viking Therapeutics | PairCorr |
Moving against Blueprint Stock
| 0.57 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.55 | GNLX | Genelux Common | PairCorr |
| 0.52 | OVID | Ovid Therapeutics Financial Report 3rd of May 2024 | PairCorr |
| 0.51 | GNFT | Genfit | PairCorr |
| 0.49 | ORGO | Organogenesis Holdings Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.